Paishuning (Senaparib) – Ovarian Cancer | HongKong DengYue Medicine

  • Generic Name/Brand Name: ​Senaparib / Paishuning®
  • Indications: Ovarian Cancer
  • Dosage Form: ​Capsule
  • Specification: 20 mg × 75 capsules/box

Senaparib Application Scope

Indication: Treatment of ovarian cancer in patients with germline or somatic BRCA-mutated advanced or recurrent disease.

paishuning senaparib
paishuning senaparib

SenaparibCharacteristics

  • Ingredients: Senaparib (PARP inhibitor).

  • Properties:​ Oral, small-molecule PARP inhibitor; blocks DNA repair in tumor cells, leading to cell death.

  • Packaging Specification:​ 20 mg × 75 capsules/box

  • Storage:​ Store at 20–25 °C, protect from moisture and light.

  • Expiry Date: As printed on the package.

  • Executive Standard: ​Per registered product quality standard.

  • Approval Number: As indicated on label.

  • Date of Revision: As printed on package insert.

  • Manufacturer: Beigene / BeiGene Ltd.

Guidelines for the Use of Paishuning

  • Dosage and Administration:

    • Recommended Dose: 20–30 mg/day (depending on regimen and patient tolerance).

    • Administration: Swallow capsules whole; do not chew or crush.

    • Missed Dose:​ Take as soon as remembered; do not double the next dose.

  • Adverse Reactions:

    • Common Adverse Reactions: Nausea, vomiting, fatigue, anemia, thrombocytopenia, leukopenia, diarrhea, decreased appetite.

    • Serious Adverse Reactions: Myelosuppression (severe anemia, thrombocytopenia, neutropenia), secondary malignancies (rare), gastrointestinal toxicity, fatigue.

  • Contraindications:

    • Hypersensitivity to it or excipients.

    • Pregnancy and breastfeeding.

  • Precautions:

    • Monitor blood counts regularly.

    • Adjust dose for hematologic toxicity.

    • Avoid live vaccines during treatment.

    • Contraception advised during and after therapy.

Senaparib Interactions

  • CYP3A inhibitors/inducers may alter it exposure.

  • Co-administration with other myelosuppressive agents may increase hematologic toxicity.

  • Monitor concomitant drugs with narrow therapeutic index.

 

Note:

  • If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
  •  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.
Contact Us
Contact Form Demo